Cargando…
Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)
BACKGROUND: The use of imatinib mesylate is associated with a progression free survival of 41 months in first line treatment of metastatic or locally advanced gastrointestinal stromal tumors (GIST) and other studies approved that adjuvant imatinib treatment improves the recurrence-free survival in p...
Autores principales: | Seidel, Christoph, Fenner, Martin, Länger, Florian, Bantel, Heike, Ganser, Arnold, Grünwald, Viktor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404905/ https://www.ncbi.nlm.nih.gov/pubmed/22612794 http://dx.doi.org/10.1186/1471-2407-12-186 |
Ejemplares similares
-
Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010) -
Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
por: Mohammadi, Mahmoud, et al.
Publicado: (2023) -
Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy
por: Da Riva, Luca, et al.
Publicado: (2011) -
Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013) -
Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)